Oncothermia is a method of non-invasive modulated electromagnetic hyperthermia, complementary in the treatment against cancer, which promotes a natural regulatory process of the body. The brand Oncotherm® was founded in 1988 by Professor Dr. András Szász, as an initiative for the development and research of the electro-hyperthermia method in the treatment of cancer.

Treatment with Oncothermia started in Germany 25 years ago, and is currently used in more than 25 countries. Only in Germany is it in 4 hospitals and in more than 50 clinics functioning effectively. Every year more than 100,000 annual treatments are carried out worldwide

At the Oncothermia Barcelona Unit is the latest generation model: EHY-2000 plus, the latest technology to offer the best results

Modelo EHY-2000 de Oncothermia

About Oncothermia:

  • Oncothermia is active in all solid tumors.
  • No side effects, rare contraindications.
  • Energy absorption combined with modulated electric field.
  • Tumor tissue is treated selectively by destroying only the malignant tissue
  • Healthy tissue is not affected.
  • The effectiveness of chemotherapy and radiotherapy improves with treatment.
  • Restores intercellular junctions, suppresses dissemination (metastasis).
  • Oncothermia induces immunogenic cell death.
  • It improves the quality of life, reduces the side effects of other treatments.
  • A proven method for 30 years with more than 100,000 treatments per year.

Dr Ou’s team, from Cancer Center, Clifford Hospital, Guangzhou, University of Medicine, China, published in the journal Eur J Pharm Sci. 2017 Nov 15; 109: 412-418, results on the synergy of intravenous Vitamin C and Oncothermia.

Vitamin C intravenously (VitC) and Oncothermia (electrohyperthermia modulated (mEHT)) have been used in medical centers for integrative medicine for the treatment of cancer, for many years. However, no pharmacokinetic study had been planned to assess Chinese cancer patients.

A clinical trial was conducted to evaluate safety and pharmacokinetics in patients with stage III-IV non-small cell lung cancer (NSCLC). A total of 35 patients with lung cancer (NSCLC) were included. A total of 15 patients with stage III-IV who entered the phase I study were selected. They were randomized allocated into 3 groups, and received doses 1.0, 1.2, 1.5 g/kg AA infusions. Participants in the first group received intravenous AA (IVAA) when mEHT was finished, in the second group IVAA was administered simultaneously with mEHT and in the third group IVAA was applied first, and followed with mEHT. The process was applied 3 times a week (every other day, weekend days off) for 4 weeks. We found that fasting plasma AA levels were significantly correlated with stage of the disease. Peak concentration of AA was significantly higher in the simultaneous treatments than in other combinations with mEHT or in solely IVAA-managed groups. 


IVAA synergy with simultaneous mEHT is safe. The concomitant application significantly increases the plasma AA level for NSCLC patients wiht non-small cell lung cancer (NSCLC).